Clinical trials: Real World Study
Protein Intolerance
A2 GUM Post-Market Effectiveness Study
This is a post-market, real-life effectiveness study of A2 growing up milk on toddlers' gut comfort.
- Trial name
- NCT03698058
- Testing
- Toddler milk
- Where
- China
- Volunteers
- 387 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Nasopharyngeal Carcinoma
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
- Trial name
- NCT04387266
- Testing
- modified reduce-volume target IMRT
- Where
- China
- Volunteers
- 471 people
- Sponsor
- Fujian Cancer Hospital
Idiopathic Pulmonary Fibrosis
Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This single arm, post-authorisation study is designed to evaluate the long-term safety of pirfenidone in participants with IPF. The enrolment of participants will be completed within approximately 24 months.
- Trial name
- NCT02699879
- Testing
- Pirfenidone
- Where
- 106 sites in Austria, Denmark and 8 more
- Volunteers
- 1,009 people
- Sponsor
- Hoffmann-La Roche
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Lung Neoplasms
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records.
- Trial name
- DeniLA (NCT07109154)
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Aspergillus Infection, Febrile Neutropenia
Ampholipad Real-World Data in Taiwan
A retrospective, post-marketing, multi-center chart review study includes patients who had been prescribed Ampholipad.
- Conditions
- Aspergillus Infection, Febrile Neutropenia, Candida Infection, Fungal Infection
- Trial name
- NCT03641131
- Where
- 6 sites in Taiwan
- Volunteers
- 102 people
- Sponsor
- Taiwan Liposome Company
Venous Vascular Closure, Electrophysiology Study
Mobilization and Outcomes After Venous Closure
The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in…
- Trial name
- MOVE (NCT07246902)
- Testing
- MYNX CONTROLTM VENOUS Vascular Closure Device
- Where
- 9 sites in United States
- Volunteers
- 339 people
- Sponsor
- Cordis US Corp.
Breast Cancer
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and…
- Trial name
- NCT06340165
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Hospital of Jilin University
Chemotherapy Induced Nausea and Vomiting
Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia
This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for prophylaxis against chemotherapy-induced nausea…
- Trial name
- NCT06756022
- Testing
- Dolasetron mesylate injection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Anhui Provincial Children's Hospital
Lung Cancer
Association Between Screening Behaviors and Lung Cancer Spectrum
The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting.
- Trial name
- NCT07626177
- Where
- China
- Volunteers
- 5,390 people
- Sponsor
- Fudan University
Vitiligo
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life.
- Trial name
- NCT07153666
- Testing
- Ruxolitinib 1.5% Cream BID
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Peking University Third Hospital
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR C19 IL (NCT05712096)
- Testing
- EVUSHELD
- Where
- Israel
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Cow's Milk Protein Allergy (CMPA), Food Hypersensitivity
SMASH: Study to Evaluate the Clinical Efficacy of an Extensively Hydrolysed Infant Formula With Synbiotics and a Human Milk Oligosaccharide (HMO) in Infants With Cow's Milk Protein Allergy (CMPA)
Cow's milk protein allergy (CMPA) is one of the most common food allergies in infants, with an estimated prevalence between 2% and 5%.
- Conditions
- Cow's Milk Protein Allergy (CMPA), Food Hypersensitivity, Infant Nutrition Disorders, Gut Microbiota
- Trial name
- SMASH (NCT07342621)
- Where
- 13 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Outcomes'10
Lysosomal Disease
A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico
During the COVID-19 pandemic, home treatment for conditions such as Fabry, Gaucher or Hunter became important because it is easier for people to stick to their treatment if medicines that need to be given as infusion (called…
- Trial name
- NCT07494058
- Testing
- No intervention
- Where
- Mexico
- Volunteers
- 232 people
- Sponsor
- Takeda
Ovarian Cancer
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.
Ovarian cancer is the second fatal gynecological cancer. More than 70% of ovarian cancer patients are diagnosed as advanced. Olaparib is the first oral poly adenosine diphosphate-ribose polymerase inhibitor (PAPPi) approved by…
- Trial name
- NCT04699006
- Where
- China
- Volunteers
- 245 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Malignant Tumor
Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors
To report the patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital in the next 10 years, and collect the postoperative complications and limb function of these patients.
- Trial name
- NCT05616195
- Testing
- 3D printed bone prosthesis replacement surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Henan Cancer Hospital
Covid19
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil
The present test-negative design study aims to estimate the real-world effectiveness of Pfizer-BioNTech BNT162b2 mRNA vaccine on symptomatic SARS-CoV-2 infection and its consequences following a mass vaccination campaign in the…
- Trial name
- NCT05052307
- Testing
- Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, CoronaVac COVID-19 vaccine, ChAdOx1 nCoV-19 Covid-19 Vaccine
- Where
- 3 sites in Brazil
- Volunteers
- 4,574 people
- Sponsor
- Hospital Moinhos de Vento
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S
Chronic Thromboembolic Pulmonary Hypertension
Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China
The Change Database is a prospective, observational multi-center disease registry, which will collect data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) in China.
- Trial name
- NCT05311072
- Testing
- pulmonary endarterectomy or balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- China-Japan Friendship Hospital
Wound Healing
Cell Suspension With Biologic Dressing for Burn Wounds
This study is a prospective, multicenter, real-world observational study. It aims to evaluate the effectiveness and safety of a combined therapy-autologous epidermal cell suspension followed by biological dressing (porcine…
- Trial name
- NCT07555418
- Testing
- Autologous Epidermal Cell Suspension
- Volunteers
- 386 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University